Company news

Phio Pharmaceuticals Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

National Spotlight Features Phio’s Innovative RNAi Technology Platform

April 2, 2024

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

April 1, 2024

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

March 20, 2024

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

March 12, 2024

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

March 5, 2024

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

January 30, 2024

Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds

December 6, 2023

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

November 8, 2023

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

November 2, 2023

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 11, 2023

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

October 10, 2023

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

August 20, 2023

Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

May 30, 2023

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

May 23, 2023

Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

May 17, 2023

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

May 15, 2023

Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL

April 17, 2023

Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 17, 2023

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity

April 16, 2023

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

March 21, 2023

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

February 21, 2023

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

February 12, 2023

Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

February 9, 2023

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors

January 5, 2023

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

December 20, 2022

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

November 9, 2022

Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 5, 2022

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman

September 28, 2022

Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

September 21, 2022

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

September 11, 2022

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022

Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting

June 5, 2022

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

May 15, 2022

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

May 4, 2022

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

May 2, 2022

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022

May 1, 2022

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

May 1, 2022

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma

April 25, 2022

Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022

April 7, 2022

Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update

March 21, 2022

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022

March 7, 2022

Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

February 21, 2022

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

January 10, 2022

Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

October 17, 2021

Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021

September 29, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 9 decks. Every deck is listed under its year.